This synthetic lethality will be best leveraged using BRAF inhibitors such as vemurafenib, which specifically inhibit ERK1/2 signalling in BRAFV600-mutant tumour cells, but may also transform the potential of MEKi and ERKi in ERK1/2-addicted melanoma tumour cells. The gene discussed is MAPK3; the disease is neoplasm.